13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies identified a CDK7/CDK12/CDK13 inhibitor that could help treat ovarian cancer. Screening of 42 small molecules targeting transcriptional and/or epigenetic components in two human ovarian cancer cell lines...
19:06 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
18:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Nov. 27 after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:49 , Nov 29, 2018 |  BC Extra  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
21:20 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer In vitro , cell culture and mouse studies identified a CDK9 inhibitor that could help treat colorectal and other cancers. Screening of a natural product library followed by chemical synthesis and...
15:29 , Nov 8, 2018 |  BC Innovations  |  Translation in Brief

Solid plans for CDK9

A team led by Temple University scientists has shed light on a new epigenetic mechanism behind a known cancer target, cyclin dependent kinase 9 (CDK9), that may broaden the scope of CDK9 inhibitors to include...
17:52 , Oct 26, 2018 |  BC Week In Review  |  Company News

Ultragenyx exercises option to Regenxbio gene therapy

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it will exercise its option under a 2015 deal to acquire exclusive rights from RegenxBio Inc. (NASDAQ:RGNX) to develop and commercialize a gene therapy to treat cyclin...
16:57 , Oct 26, 2018 |  BC Week In Review  |  Company News

NICE recommends against abemaciclib for untreated breast cancer

The U.K.'s NICE issued draft guidance recommending against the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer. NICE said...
17:06 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Velicept raises additional $15M in series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised $15 million in a series B round extension led by Samsara BioCapital. Existing investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...